Insider Trading April 1, 2026

Horizon Kinetics Adds One Share to Its Texas Pacific Land Holding at $470

Minor transaction recorded as broader analyst enthusiasm and investor interest lift TPL shares

By Sofia Navarro TPL
Horizon Kinetics Adds One Share to Its Texas Pacific Land Holding at $470
TPL

Horizon Kinetics Asset Management LLC, already a roughly 10% holder of Texas Pacific Land Corp (NYSE: TPL), reported buying a single share of the company on March 31, 2026 for $470.18. The firm now directly holds 3,467,937 TPL shares. The trade comes amid a mixed quarterly report and a significant price-target increase from KeyBanc, which cited power generation, data center opportunities and strength in the water business on TPL's surface acreage.

Key Points

  • Horizon Kinetics Asset Management LLC, a roughly 10% owner of Texas Pacific Land, reported buying 1 share on March 31, 2026 at $470.18 - bringing its direct holding to 3,467,937 shares.
  • Texas Pacific Land posted Q4 2025 EPS of $1.79 and revenue of $212 million, both slightly below consensus forecasts of $1.83 and $214 million respectively.
  • KeyBanc raised its price target on TPL stock to $639 from $350 and maintained an Overweight rating, citing power generation and data center opportunities on surface acreage and strong water-segment trends.

Horizon Kinetics Asset Management LLC, which holds about ten percent of Texas Pacific Land Corp (NYSE: TPL), disclosed a direct purchase of one share of the company’s common stock on March 31, 2026. The reported per-share price for the transaction was $470.18, with the total value recorded as $470. Following the purchase, Horizon Kinetics’ direct ownership in Texas Pacific Land stands at 3,467,937 shares.


Texas Pacific Land’s most recent quarterly results show modest shortfalls versus expectations. For the fourth quarter of 2025 the company reported earnings per share of $1.79, below the consensus forecast of $1.83. Quarterly revenue was $212 million, narrowly missing the projected $214 million.

Shortly after the earnings release, KeyBanc adjusted its valuation view for the company. The firm raised its price target on Texas Pacific Land shares to $639 from $350 while retaining an Overweight rating. KeyBanc highlighted developments tied to power generation and data center prospects on TPL’s surface acreage as drivers of the revised outlook. Analysts at the bank also pointed to strong trends in the company’s water segment.

KeyBanc additionally reported a notable uptick in client interest during 2026, noting that inquiries have risen across investor types. The reported sources of increased inquiries include long-only managers, traditional long/short funds, and generalist investors.

Market performance to date reflects heightened attention: Texas Pacific Land has appreciated 74% year-to-date, a sharp contrast with a 1% increase recorded for the S&P 500 over the same period.


This disclosure of a single-share purchase by a large holder arrives against a backdrop of analyst optimism and rising investor interest, alongside quarterly results that slightly missed expectations.

Risks

  • Quarterly results for Q4 2025 missed consensus forecasts on both EPS and revenue, highlighting potential near-term operational or timing risks for earnings - this impacts equity investors and REIT/land-asset market participants.
  • Investor interest, while elevated, comes from a diverse set of market participants; heightened inquiries do not guarantee sustained capital flows and could introduce volatility for the stock and related sectors.
  • Valuation shifts driven by emerging opportunities such as power generation and data center development are contingent on execution and market demand for those uses of surface acreage, affecting the company’s real estate and energy-related exposure.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026